A laboratory on Long Island has found a breakthrough in the fight against pancreatic cancer that can “intercept” its spread.

Researchers have identified a new mechanism to delay KRAS-mutated pancreatic cancer development in mice.

Targeting FGFR2 may prevent or delay some KRAS-mutated pancreatic cancers The preclinical study has implications for pancreatic cancer interception efforts Peer-Reviewed Publication ...

Notably, FGFR2 expression in murine precancerous lesions correlated with an increase in mutant KRAS signaling. "We know that precancerous pancreatic lesions often carry KRAS mutations," said Tonelli.

Scientists have found a way to 'intercept' pancreatic cancer. By inhibiting the cancer gene FGFR2, they were able to slow tumor formation. By targeting the FGFR2 and EGFR proteins, they were able ...

Its activation enhances redox imbalance, which fosters survival signaling and apoptosis resistance. Studies indicate that ROS1, along with other receptor tyrosine kinases, such as FGFR1 and FGFR2, can ...

The above results confirm that the combination of SHP099 and AZD4547 has a synergistic effect on tumor cell killing and apoptosis in FGFR2-amplified GC in vitro.

Anticancer Agent "TASFYGO Tablets 35mg" (Tasurgratinib Succinate) Launches in Japan for Biliary Tract Cancer with FGFR2 Gene Fusion or Rearrangements ...

TOKYO, Sept 24, 2024--- Anticancer Agent "Tasfygo (R) Tablets 35 mg" Approved in Japan for Biliary Tract Cancer with FGFR2 Gene Fusions or Rearrangements. Eisai Co., Ltd. announced today that it ...

Evidence-based recommendations on futibatinib (Lytgobi) for previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangement in adults. Last reviewed: 11 September 2024 Next review: ...

While the FDA approval of Truseltiq for FGFR2-positive cholangiocarcinoma was withdrawn, there are still other viable treatment options, an expert said.